Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
ABN: 86 139 590 319
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: enquiries@ndr.org.au
Web: www.ndr.org.au

EXPEDITION

An Alzheimer's Research Study

Aim

To evaluate the effectiveness of an investigational medication at slowing the impact of Alzheimer's disease (AD) on memory and daily activities when given as an intravenous (IV) infusion once every 4 weeks.

Phase III

Randomized, double blinded, placebo controlled

Hypothesis

Passive immunization with solanezumab, a monoclonal antibody, directed to a specific region of the Aβ protein will slow the cognitive and functional decline of AD as compared with placebo.

- Two co-primary outcomes: ADAS-Cog and the ADCS-ADL.
- Decline in cognition and function at the end of the treatment (18 months) will be significantly less than placebo.

TGA Trial 2009/0291

Funding

- Eli Lilly Australia Pty Limited
- York Neuroscience Discovery Inc

Criteria

To be eligible for the Expedition Study participants must:

- be 55 years or older and generally healthy,
- have mild to moderate Alzheimer's disease, and
- have a reliable carer who can assist him or her during the study.

Status

Enrolment completed; study ongoing

Ethics approval

Mount Hospital Ethics Committee (EC51.2)

Contact

Professor Peter K Panegyres
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: research@ndr.org.au